Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey.
Adherence
Antipsychotic
Bipolar I disorder
Bipolar disorder
Preference
Side effects
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
06 07 2020
06 07 2020
Historique:
received:
06
02
2020
accepted:
25
06
2020
entrez:
8
7
2020
pubmed:
8
7
2020
medline:
22
12
2020
Statut:
epublish
Résumé
Oral antipsychotic (AP) medications are frequently prescribed to people with bipolar I disorder (BD-I). A cross-sectional online survey examined the experiences of people living with BD-I with a history of recent AP use. Adults with self-reported physician-diagnosed BD-I (N = 200) who received oral APs during the prior year completed a survey on AP-related experiences, including side effects and their perceived burden on social functioning, adherence, and work. Items also assessed preferences for trade-offs (balancing symptom management and side effects) when considering a hypothetical new AP. The perceived impact of specific, prevalent side effects on adherence, work, and preferences for a hypothetical AP were also examined. Analyses were descriptive. The survey sample had a mean age of 43.2 (SD = 12.4) years, was 60% female, and 31% nonwhite. Almost all participants (98%) had experienced AP side effects. Common self-reported side effects were feeling drowsy or tired (83%), lack of emotion (79%), anxiety (79%), dry mouth (76%), and weight gain (76%). Weight gain was cited as the most bothersome side effect, rated by most participants (68%) as "very" or "extremely bothersome." Nearly half of participants (49%) reported that AP side effects negatively impacted their job performance; almost all (92%) reported that side effects - most commonly anxiety and lack of emotion - negatively impacted social relationships (e.g., family or romantic partners). The most commonly-reported reason for stopping AP use was dislike of side effects (48%). Side effects most likely to lead to stopping or taking less of AP treatment included "feeling like a 'zombie'" (29%), feeling drowsy or tired (25%), and weight gain (24%). When considering a hypothetical new AP, the most common side effects participants wanted to avoid included AP-induced anxiety (50%), weight gain (48%), and "feeling like a 'zombie'" (47%). Side effects of APs were both common and bothersome, and impacted social functioning, adherence, and work. Findings highlight the prevailing unmet need for new APs with more favorable benefit-risk profiles.
Sections du résumé
BACKGROUND
Oral antipsychotic (AP) medications are frequently prescribed to people with bipolar I disorder (BD-I). A cross-sectional online survey examined the experiences of people living with BD-I with a history of recent AP use.
METHODS
Adults with self-reported physician-diagnosed BD-I (N = 200) who received oral APs during the prior year completed a survey on AP-related experiences, including side effects and their perceived burden on social functioning, adherence, and work. Items also assessed preferences for trade-offs (balancing symptom management and side effects) when considering a hypothetical new AP. The perceived impact of specific, prevalent side effects on adherence, work, and preferences for a hypothetical AP were also examined. Analyses were descriptive.
RESULTS
The survey sample had a mean age of 43.2 (SD = 12.4) years, was 60% female, and 31% nonwhite. Almost all participants (98%) had experienced AP side effects. Common self-reported side effects were feeling drowsy or tired (83%), lack of emotion (79%), anxiety (79%), dry mouth (76%), and weight gain (76%). Weight gain was cited as the most bothersome side effect, rated by most participants (68%) as "very" or "extremely bothersome." Nearly half of participants (49%) reported that AP side effects negatively impacted their job performance; almost all (92%) reported that side effects - most commonly anxiety and lack of emotion - negatively impacted social relationships (e.g., family or romantic partners). The most commonly-reported reason for stopping AP use was dislike of side effects (48%). Side effects most likely to lead to stopping or taking less of AP treatment included "feeling like a 'zombie'" (29%), feeling drowsy or tired (25%), and weight gain (24%). When considering a hypothetical new AP, the most common side effects participants wanted to avoid included AP-induced anxiety (50%), weight gain (48%), and "feeling like a 'zombie'" (47%).
CONCLUSIONS
Side effects of APs were both common and bothersome, and impacted social functioning, adherence, and work. Findings highlight the prevailing unmet need for new APs with more favorable benefit-risk profiles.
Identifiants
pubmed: 32631362
doi: 10.1186/s12888-020-02767-x
pii: 10.1186/s12888-020-02767-x
pmc: PMC7371473
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
354Références
Ann Gen Psychiatry. 2009 Feb 18;8:7
pubmed: 19226463
Value Health. 2005 Nov-Dec;8 Suppl 1:S9-S24
pubmed: 16336491
Bipolar Disord. 2004 Dec;6(6):460-9
pubmed: 15541061
PLoS One. 2011;6(12):e28725
pubmed: 22163329
Patient Prefer Adherence. 2017 Mar 03;11:449-468
pubmed: 28424542
Lancet. 2016 Apr 9;387(10027):1561-1572
pubmed: 26388529
Int J Mol Sci. 2018 Jul 23;19(7):
pubmed: 30041458
J Affect Disord. 2013 Dec;151(3):1009-15
pubmed: 24051101
Patient Prefer Adherence. 2013;7:89-94
pubmed: 23378745
J Affect Disord. 2001 Dec;67(1-3):45-59
pubmed: 11869752
Acta Psychiatr Scand. 2016 Feb;133(2):144-153
pubmed: 26114830
J Clin Psychiatry. 2002 Feb;63(2):120-5
pubmed: 11874212
Neuropsychiatr Dis Treat. 2016 Mar 31;12:719-35
pubmed: 27099503
Int J Bipolar Disord. 2017 Dec;5(1):29
pubmed: 28589489
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654
pubmed: 20238348
Bipolar Disord. 2016 Mar;18(2):192-9
pubmed: 26890335
J Affect Disord. 2006 Jun;92(2-3):309-12
pubmed: 16524631
Bipolar Disord. 2006 Jun;8(3):232-41
pubmed: 16696824
Clin Psychol Psychother. 2017 Jul;24(4):911-918
pubmed: 27862615
Med Care. 2007 Jun;45(6):545-52
pubmed: 17515782
Am J Psychiatry. 1999 May;156(5):702-9
pubmed: 10327902
Psychiatr Clin North Am. 1983 Mar;6(1):175-92
pubmed: 6889171
J Affect Disord. 2001 Jun;65(1):85-93
pubmed: 11426515
J Clin Psychiatry. 1996 Jul;57(7):292-7
pubmed: 8666570
Curr Neuropharmacol. 2017 Apr;15(3):353-358
pubmed: 28503106
J Clin Psychiatry. 2008;69 Suppl 5:9-15
pubmed: 19265635
Acta Psychiatr Scand. 2002 Mar;105(3):164-72
pubmed: 11939969
Indian J Psychiatry. 2015 Jul;57(Suppl 2):S252-63
pubmed: 26330643
Psychiatry Res. 2011 Nov 30;190(1):110-4
pubmed: 21571375
World J Psychiatry. 2016 Dec 22;6(4):399-409
pubmed: 28078204
Bipolar Disord. 2005 Apr;7(2):119-25
pubmed: 15762852
Bipolar Disord. 2016 Mar;18(2):174-82
pubmed: 26890465
J Affect Disord. 2009 Jun;115(3):360-6
pubmed: 18996600
J Affect Disord. 2014 Feb;155:110-7
pubmed: 24262639